Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4335 Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study

Introduction: The most common side effect of radioligand therapy is renal damage, early or late. However, limited data exist for the long-term side effects and impact of additional risk factors on renal function in patients treated with PRRT.

Conference:

Presenting Author: Sygula A

Authors: Sygula A, Kropinska A, Kotecka-Blicharz A, Gawlik T, Wycislik M,

Keywords: Neuroendocrine tumour, PRRT, nephrotoxicity, yttrium-90, lutetium-177,

#4332 Efficacy of SIRT radioembolisation of liver metastases of neuroendocrine tumours (NETs): A single institution experience

Introduction: Majority of NET patients develop liver metastases (NET-LM). Improved treatment of NET-LM may prolong survival. In case of liver-dominant metastatic disease, local radionuclide treatment using microspheres could be considered.

Conference:

Presenting Author: Kropinska A

Authors: Kropinska A, Gola M, Sygula A, Hamm M, Ledwon A,

Keywords: SIRT, radioembolisation, neuroendocrine tumour, liver metastasis,

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3556 Radioembolization of neuroendocrine neoplasms liver metastases: Efficacy and toxicity

Introduction: In patients with unresectable liver metastases, radioembolization has been used to treat tumors from a range of cancers, including neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Gola M, Syguła A, Szynkiewicz J, Olczyk T, Kalemba M,

Keywords: radioemolisation liver metastasis,

#3396 Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuro-endocrine tumor liver metastases

Introduction: In radioembolization, response is achieved through the irradiation and damaging of tumor DNA, while treatment toxicity is mainly related to healthy liver dose. Therefore, optimizing the dose in tumors while minimizing the healthy liver dose is deemed important. However, for hepatic metastases of neuroendocrine tumors, a dose-response relationship has not been established yet.

Conference:

Presenting Author: Ebbers S

Authors: Ebbers S, van Roekel C, Braat M, Barentsz M, Lam M,

Keywords: dose-response, neuroendocrine neoplasm, SIRT, 90y, radioembolization, liver metastasis,